
Feature|Videos|January 2, 2025
FDA Regulations for CAR T-cell Therapy
Examining hurdles surrounding FDA approval and how to streamline the process
Advertisement
Episodes in this series

The regulatory landscape for CAR T-cell therapies is constantly evolving with the FDA establishing their own guidelines needed for approval. Often, the approval can be long and difficult to obtain. Panelists examine their own strategies that have increased collaboration and support from the FDA.
Advertisement
Related to this article

FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.

FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.

FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention.

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.

Ignite Proteomics’ senior clinical research scientist discusses how flaws in testing tumors may lead to some patients not receiving the correct treatment.

argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Requests Updated Safety Label Warning Across All GLP-1 Receptor Agonist for Potential Risk of NAION
2
AstraZeneca Acquires Omniose, Adding Bioconjugation Platform to Vaccine Pipeline
3
FDA Approves asundexian for Secondary Stroke Risk Reduction
4
Where AI Can Strengthen Clinical Research, and Where Patient Input is More Important
5










